CPP-oligonucleotide conjugates can be powerful research tools, but they are not simple extensions of standard peptide synthesis or routine oligonucleotide production. A cell-penetrating peptide (CPP) may introduce strong cationic charge, hydrophobic amino acid regions, secondary-structure tendencies, and adsorption behavior, while the oligonucleotide component contributes high polarity, anionic phosphate groups, UV absorbance, sequence-dependent stability, and possible length-related analytical complexity. When these two molecular classes are covalently combined, purification and quality control often become more demanding than either component alone.
For researchers ordering custom CPP-oligonucleotide conjugates, the key question is not only whether a conjugation reaction can be performed. The more practical question is whether the final material can be separated from unconjugated peptide, unconjugated oligonucleotide, truncated sequences, side products, salts, counterions, and closely related conjugation variants with enough confidence for the intended experiment. A conjugate used for early screening may not require the same analytical package as one used for quantitative uptake studies or preclinical exploratory research, but every project benefits from realistic expectations before synthesis begins.
This guide explains why CPP-oligonucleotide conjugates require careful purification and analytical confirmation, how different purification strategies may be selected, which characterization methods are commonly considered, and what information should be included in a useful QC report. It is intended for researchers, analytical scientists, procurement teams, and project leaders who need to define specifications for custom research-use conjugates before downstream experiments begin.
Quality control for CPP-oligonucleotide conjugates is challenging because the final molecule carries analytical features from both peptide chemistry and oligonucleotide chemistry. A conventional peptide may be assessed primarily by RP-HPLC and mass spectrometry, while a standard oligonucleotide may be evaluated by ion-exchange HPLC, IP-RP-HPLC, mass spectrometry, capillary electrophoresis, UV absorbance, or gel-based methods depending on length and modification. A CPP-oligonucleotide conjugate may require a method that can resolve both peptide-related and oligo-related impurities while still allowing accurate detection of the intact conjugate.
CPPs are frequently enriched in cationic residues such as arginine or lysine, amphipathic residues, or hydrophobic motifs that support membrane interaction. Oligonucleotides, by contrast, contain a negatively charged phosphate backbone. The resulting conjugate may show partially neutralized charge, broad chromatographic behavior, unusual retention, or multiple ionic states depending on pH, salt concentration, counterion, oligonucleotide chemistry, and peptide sequence.
This charge and hydrophobicity balance affects purification. A conjugate with a highly basic CPP may interact strongly with silanol groups, ion-exchange resins, sample tubes, or residual anionic impurities. A conjugate with a hydrophobic CPP may retain strongly on reversed-phase media but also show aggregation or poor recovery. A conjugate with a long oligonucleotide may be too polar for conventional peptide-oriented reversed-phase methods unless mobile phase, ion-pairing conditions, temperature, and column chemistry are carefully adjusted.
The practical result is that a single "standard HPLC method" may not work for all CPP-oligonucleotide conjugates. Method selection should be driven by sequence, oligonucleotide length, linkage chemistry, expected impurities, required purity, and final formulation needs.
CPP-oligonucleotide conjugation can generate impurity profiles that are difficult to interpret. Potential impurities may include unconjugated peptide, unconjugated oligonucleotide, truncated peptide sequences, failure sequences from oligonucleotide synthesis, hydrolyzed activated intermediates, partially deprotected species, oxidized peptide residues, disulfide-related byproducts, linker-derived side products, and incomplete conjugation products.
Some impurities may be chemically different but chromatographically close to the desired product. For example, an unconjugated oligonucleotide may absorb strongly at 260 nm and appear prominent in UV traces, while a peptide-rich impurity may be more visible at 214 nm. A conjugate missing a small terminal residue, a protecting group, or a linker fragment may have a similar retention profile to the target product. When the oligonucleotide is long, mass confirmation may also require careful deconvolution or an analytical method designed for high-mass, multiply charged molecules.
Because of these overlapping signals, HPLC purity alone may not be enough to confirm that the main peak is the intended conjugate. Identity confirmation and purity assessment should be treated as related but separate QC questions.
Some CPP-oligonucleotide conjugates show aggregation, adsorption, or recovery loss during purification and handling. Aggregation can occur through electrostatic interaction, hydrophobic peptide association, intermolecular base stacking, secondary-structure effects, or salt-dependent complexation. Adsorption may occur on plasticware, filters, membranes, chromatography hardware, or lyophilization surfaces, especially when the molecule combines hydrophobic peptide regions with a highly charged oligonucleotide segment.
Recovery loss matters because it affects both project cost and interpretation of yield. A crude conjugation reaction may contain the desired product, but aggressive purification conditions, repeated concentration steps, or unsuitable desalting procedures can reduce isolated amount. For procurement teams, this means that requested final quantity should be discussed together with expected recovery, analytical requirements, and final formulation. For researchers, it means that low yield is not always a synthesis failure; it may reflect purification difficulty, solubility limitations, or product instability under certain processing conditions.
Purification of CPP-oligonucleotide conjugates should be planned around the properties of the intact conjugate and the impurities that must be removed. The best approach may involve reversed-phase chromatography, ion-exchange chromatography, mixed-mode methods, desalting, buffer exchange, or a combination of approaches. The goal is not simply to create a sharp chromatographic peak, but to isolate material that is chemically correct, sufficiently pure, compatible with the downstream application, and stable under recommended storage conditions.
Reversed-phase HPLC is widely used in peptide purification and may be useful for CPP-oligonucleotide conjugates when hydrophobic differences between the conjugate and impurities are large enough to support separation. The peptide component often contributes retention, while the oligonucleotide component may require modified mobile-phase conditions to achieve suitable peak shape and recovery.
Method development may include optimization of column chemistry, pore size, temperature, organic solvent gradient, pH, ion-pairing reagent, and detection wavelength. Detection at 214 nm may emphasize peptide bonds, while detection around 260 nm emphasizes the oligonucleotide component. Monitoring more than one wavelength can help distinguish peptide-rich and oligo-rich peaks during analytical assessment.
RP-HPLC can be useful when the desired conjugate differs significantly in hydrophobicity from the unconjugated oligonucleotide or peptide. However, it may be less effective when impurities have similar hydrophobicity or when ion-pairing conditions complicate downstream desalting and mass spectrometry. For sensitive downstream assays, residual mobile-phase additives and counterions should be considered during final processing.
Ion-exchange chromatography can be valuable when charge differences are more useful than hydrophobicity differences. Because oligonucleotides carry multiple negative charges and many CPPs carry positive charges, the net charge of the conjugate may differ from unconjugated oligonucleotide, unconjugated peptide, and shorter oligo impurities. Anion-exchange methods may help separate oligonucleotide-related species, while cation-exchange behavior may be influenced by strongly basic CPP sequences.
Mixed-mode chromatography can be considered when a conjugate requires both ionic and hydrophobic selectivity. This may be helpful for constructs where RP-HPLC alone gives broad peaks or where ion-exchange alone does not sufficiently resolve closely related conjugation products. Mixed-mode methods can sometimes improve selectivity, but they also require careful optimization because small changes in salt, pH, organic solvent, or gradient conditions can shift retention substantially.
The main advantage of ion-exchange or mixed-mode purification is selectivity. The main limitation is that method development can be project-specific, and final fractions may require desalting or buffer exchange before lyophilization, concentration determination, or biological testing.
Desalting and buffer exchange are important finishing steps after chromatographic purification. Purified CPP-oligonucleotide conjugates may contain salts, ion-pairing reagents, volatile buffers, counterions, or residual solvents from purification. These components can affect concentration measurement, lyophilization behavior, cell-based assays, hybridization assays, and storage stability.
Desalting approaches may include size-exclusion desalting, ultrafiltration, dialysis, solid-phase extraction, precipitation, or repeated lyophilization from volatile buffers, depending on molecular size and solubility. Each approach has trade-offs. Ultrafiltration may be convenient but can lead to membrane adsorption. Dialysis may be gentle but slow. Solid-phase extraction may be efficient for some constructs but unsuitable for others. Lyophilization can support storage but may require attention to residual salt and reconstitution behavior.
A practical specification should define the preferred final form where possible. For example, a researcher may request lyophilized material, a defined salt form, a specific buffer, nuclease-free water, or concentration reporting after reconstitution. If the downstream assay is sensitive to salt, organic solvent, or counterion composition, that information should be provided at the inquiry stage.
Purification scale affects method choice, achievable purity, and final recovery. A small-scale discovery conjugate may be purified analytically or semi-preparatively, while larger research batches may require scalable chromatography and additional process controls. Higher requested purity generally reduces recovery because more fractions are excluded. Difficult sequences may require multiple purification passes, which can improve purity but reduce isolated yield.
Procurement teams should avoid specifying only "highest possible purity" without considering quantity, timeline, analytical package, and application. A more useful request defines the intended use, minimum acceptable purity, required identity confirmation, final quantity needed for experiments, and whether additional reserve material is required for repeat testing. This allows the supplier to evaluate feasibility and recommend a purification strategy that balances purity, recovery, and cost.
Analytical characterization should answer several questions: Is the main product the intended CPP-oligonucleotide conjugate? How pure is the material under the selected analytical method? Are major impurities visible and interpretable? Is the molecular weight consistent with the designed construct? Is the concentration or amount reported in a way that downstream users can apply correctly?
No single analytical method is ideal for every conjugate. A reliable QC package often combines chromatographic purity assessment with mass-based identity confirmation and concentration reporting. Additional checks may be appropriate when the conjugate is long, structurally complex, fluorescently labeled, double-stranded, hybridization-dependent, or intended for cell-based functional studies.
LC-MS is commonly used to confirm identity by linking chromatographic behavior with molecular weight information. For CPP-oligonucleotide conjugates, LC-MS can help distinguish the desired conjugate from unconjugated peptide, unconjugated oligonucleotide, and some incomplete reaction products. Depending on molecular size and chemistry, electrospray ionization may produce multiply charged ions that require deconvolution to obtain the intact molecular weight.
LC-MS method development may need to account for ion-pairing reagents, salt contamination, adduct formation, oligonucleotide length, and peptide basicity. A method optimized for small peptides may not be suitable for a long oligonucleotide conjugate, while a method optimized for oligonucleotides may not fully resolve peptide-related side products. When LC-MS is requested as a release method, the expected mass, acceptable mass tolerance, and reporting format should be discussed in advance.
MALDI-TOF mass spectrometry may be useful for larger conjugates or constructs that are difficult to analyze by LC-MS under available conditions. It can provide molecular weight information for intact conjugates and may tolerate certain sample types differently from electrospray-based approaches. For some peptide-oligonucleotide conjugates, MALDI-TOF can provide a practical identity check when chromatographic separation and electrospray ionization are challenging.
The limitation is that MALDI-TOF may not provide the same chromatographically resolved impurity profile as LC-MS. Matrix selection, salt removal, sample homogeneity, and ionization efficiency can also affect spectral quality. Therefore, MALDI-TOF is often most useful when paired with HPLC or another purity method rather than used as the only QC test.
Analytical HPLC provides a purity profile under defined chromatographic conditions. It can show whether the purified product appears as a dominant peak and whether major impurities remain. For CPP-oligonucleotide conjugates, purity may be reported using UV detection at one or more wavelengths. Because peptides and oligonucleotides absorb differently, method conditions and detection wavelength should be stated clearly in the report.
Analytical HPLC purity should be interpreted as method-dependent. A product that appears highly pure under one method may reveal additional impurities under another method with different selectivity. This is especially relevant when impurities are structurally similar to the target conjugate. For high-consequence experiments, researchers may request orthogonal methods or additional identity confirmation rather than relying on a single HPLC trace.
UV quantification is commonly used for oligonucleotide-containing materials because nucleobases absorb strongly near 260 nm. For CPP-oligonucleotide conjugates, concentration estimation may be based on calculated extinction coefficients for the oligonucleotide component, with awareness that peptide residues, labels, buffers, and impurities may influence absorbance. If the conjugate contains aromatic amino acids or chromophores, absorbance at additional wavelengths may be informative.
UV-based reporting should specify whether the value refers to total absorbance-derived material, purified conjugate amount, concentration after reconstitution, or lyophilized mass. This distinction matters because salts and counterions can contribute to dry weight, while UV absorbance reflects the nucleic acid component more directly than total lyophilized mass.
Gel-based methods may be useful for certain CPP-oligonucleotide conjugates, especially when size, charge shift, duplex formation, or hybridization behavior needs to be checked. Native or denaturing gels may help compare unconjugated oligonucleotide with conjugated material, although CPP-driven charge effects can alter migration in ways that require careful interpretation.
Hybridization-related checks may be relevant when the oligonucleotide must bind a complementary strand, participate in antisense recognition, or form a duplex for downstream experiments. These checks are not always required for procurement QC, but they can be valuable when biological function depends on accessible base pairing after peptide conjugation.
| Method | Information Provided | Strength | Limitation | When Useful |
| Analytical HPLC | Purity profile and relative impurity peaks | Practical release test for batch comparison | Purity is method- and wavelength-dependent | Routine purity assessment and fraction evaluation |
| LC-MS | Molecular weight confirmation linked to chromatographic peaks | Strong identity confirmation when ionization and deconvolution are suitable | Sensitive to salt, adducts, ion-pairing conditions, and molecular size | Confirming target conjugate identity and detecting mass-related impurities |
| MALDI-TOF MS | Intact mass information | Useful for larger or difficult conjugates | Does not replace chromatographic purity profiling | Larger conjugates or constructs challenging for LC-MS |
| UV absorbance | Concentration estimate based on oligonucleotide absorbance | Simple and useful for oligo-containing products | Can be affected by buffer, labels, impurities, and extinction coefficient assumptions | Amount or concentration reporting for downstream assay setup |
| Gel-based analysis | Size or mobility comparison | Visual comparison of oligo and conjugate behavior | CPP charge can complicate migration interpretation | Duplex, size-shift, or qualitative conjugation checks |
| Hybridization-related assay | Ability to bind complementary sequence | Connects chemical identity with oligonucleotide accessibility | Usually project-specific rather than standard release QC | Antisense, siRNA, probe, or duplex-dependent research designs |
Table 1 Analytical Method Selection for CPP-Oligonucleotide Conjugates
A useful QC report should provide enough information for researchers to confirm that the received material matches the requested design and is suitable for the planned experiment. The report does not need to be overloaded with unnecessary data, but it should clearly document identity, purity, analytical method, amount or concentration, and storage recommendations.
The report should identify the conjugate by sequence, modification, linkage, and molecular formula or calculated molecular weight where applicable. It should state the peptide sequence, oligonucleotide sequence or sequence identifier, terminal modifications, linker chemistry, attachment position, and any labels or special residues. If sequence confidentiality requires abbreviated reporting, the report should still connect the batch to an agreed project identifier and specification.
Identity should be supported by mass confirmation when feasible. The report should list the calculated molecular weight and observed molecular weight, or provide a deconvoluted mass result for the intact conjugate. For larger or difficult constructs, the report should explain the method used and any relevant interpretation limits.
The purity section should state the analytical method, column or separation type, mobile-phase system or general method description, detection wavelength, chromatogram, and calculated purity. For CPP-oligonucleotide conjugates, it is helpful to specify whether purity was calculated at 214 nm, 260 nm, or another wavelength. If multiple wavelengths were used, the report should make clear which value is used as the release purity.
When relevant, the report may also note major impurity peaks or residual unconjugated starting material. This is especially useful for researchers performing cell-based experiments, where free CPP, free oligonucleotide, or small-molecule linker residues could affect interpretation.
Molecular weight confirmation helps verify that the purified product is the intended conjugate rather than a co-eluting impurity. LC-MS or MALDI-TOF data should be reported with enough detail to allow interpretation. For LC-MS, deconvoluted mass may be more useful than raw charge-state clusters for many end users. For MALDI-TOF, the report should show the observed mass peak and clarify whether the result is singly charged, adducted, or otherwise interpreted.
If the molecule is not suitable for a requested mass method, this should be communicated clearly. Alternative confirmation strategies may include orthogonal chromatography, enzymatic or chemical cleavage followed by component analysis, gel shift comparison, or hybridization-based confirmation, depending on the design.
Storage and handling information should be specific enough to prevent avoidable degradation or loss. The report or accompanying documentation should state whether the product is supplied lyophilized or in solution, recommended storage temperature, preferred reconstitution solvent, freeze-thaw precautions, light sensitivity if labeled, nuclease-control considerations, and any known solubility notes.
Many CPP-oligonucleotide conjugates are best handled using nuclease-free materials and low-binding tubes. Some may require gentle mixing rather than vigorous vortexing. Others may need gradual reconstitution, short equilibration time, or avoidance of high salt during initial dissolution. These details can make the difference between a successful first experiment and a misleading result caused by incomplete solubilization or adsorption loss.
Purity requirements should be matched to the scientific question. Over-specifying purity can increase cost and reduce recovery, while under-specifying purity can compromise downstream data. The right QC expectation depends on whether the conjugate is used for screening, cell-based testing, uptake studies, or exploratory preclinical research.
Early screening studies often compare multiple CPPs, linkers, oligonucleotide designs, or conjugation formats. In this setting, researchers may prioritize identity-confirmed material, reasonable purity, and consistent handling over maximum purity for every construct. The goal is to identify promising designs, not to finalize a development candidate.
However, screening material still requires adequate documentation. If one construct appears more active than another, researchers need confidence that the difference is not caused by free peptide, free oligonucleotide, major impurity, or concentration error. At minimum, screening studies benefit from analytical HPLC purity, mass confirmation where feasible, and clear concentration or amount reporting.
Cell-based assays are more sensitive to impurities and formulation effects. Free CPP may affect membranes, free oligonucleotide may contribute background activity, residual solvent or salts may affect cell viability, and aggregates may alter uptake. For this reason, cell-based studies usually require stronger purity expectations and careful handling instructions.
Researchers should communicate cell type, assay duration, concentration range, serum conditions, endpoint, and tolerance for formulation components. These details help define whether additional desalting, buffer exchange, sterility-related handling, endotoxin awareness, or low-binding storage recommendations should be considered. For research-use conjugates, the QC package should support interpretation of biological data without implying clinical suitability unless a separate regulated manufacturing program has been established.
Mechanistic uptake studies may require especially careful characterization because the experimental goal is often to understand how the conjugate enters cells, traffics between compartments, escapes endosomes, or reaches a target RNA. In these studies, impurities can be misleading. A small amount of free fluorescent peptide, free labeled oligonucleotide, aggregate, or unconjugated CPP may distort microscopy, flow cytometry, or uptake quantification.
Mechanistic studies may therefore require orthogonal confirmation, higher purity, label integrity checks, and careful comparison with controls. Researchers may need matched unconjugated oligonucleotide, free CPP, scrambled sequence, nonpenetrating peptide control, or cleavable versus non-cleavable linker variants. The QC plan should support these comparisons by confirming that each material is what it claims to be.
Preclinical exploratory research places greater emphasis on documentation, reproducibility, and traceability. Even when the material is for research use only, project leaders may need batch records, analytical traces, identity confirmation, purity data, storage conditions, and formulation information to support internal review or repeat studies.
In exploratory animal or translational studies, the consequences of impurity, inaccurate concentration, aggregation, or instability may be more significant than in early in vitro screening. The requested QC package should be discussed before synthesis, especially if the project requires larger quantity, repeated dosing experiments, long-term storage, or comparison across batches.
| Application | Typical Quality Concern | Suggested QC Focus | Procurement Note |
| Screening studies | Comparing multiple designs without confusing identity or concentration | HPLC purity, identity confirmation, amount reporting | Balance purity with throughput, cost, and number of constructs |
| Cell-based functional assays | Free CPP, free oligo, salts, solvent, or aggregates affecting assay readout | Higher purity, desalting or buffer exchange, clear handling guidance | Share cell type, assay medium, dose range, and endpoint |
| Mechanistic uptake studies | Misinterpreting uptake due to free label, unconjugated component, or aggregate | Orthogonal identity checks, label confirmation, control materials | Define imaging, flow cytometry, or subcellular trafficking requirements early |
| Preclinical exploratory research | Reproducibility, traceability, formulation, and stability concerns | Documented purity, mass confirmation, batch traceability, storage information | Discuss documentation expectations before quotation and synthesis |
Table 2 Purity Requirement by Application
A well-prepared inquiry helps the supplier evaluate feasibility and design an appropriate purification and QC workflow. Instead of requesting a custom CPP-oligonucleotide conjugate with only a sequence and target quantity, procurement teams should define the intended application, analytical expectations, formulation preferences, and reporting needs. This reduces ambiguity and helps avoid delays after synthesis.
Requested purity should be realistic for the sequence, scale, and intended use. For some constructs, high purity may be achievable with a single purification strategy. For others, higher purity may require multiple chromatographic steps, lower recovery, additional method development, or revised design. If a project has a strict purity threshold, it should be stated before work begins.
Researchers should also define how purity should be measured. A statement such as "95% purity" is incomplete unless the analytical method and detection wavelength are understood. For CPP-oligonucleotide conjugates, purity by RP-HPLC at 260 nm may not tell the same story as purity by another chromatographic mode or wavelength. When the application is sensitive, method-specific purity expectations should be discussed.
The required analytical method should be selected according to the question being answered. Analytical HPLC can support purity assessment. LC-MS or MALDI-TOF can support molecular weight confirmation. UV absorbance can support concentration estimation. Gel or hybridization-related checks may support size, duplex formation, or oligonucleotide accessibility.
A strong procurement request states which data are required for release and which are optional. For example, a project may require HPLC purity and observed molecular weight for every conjugate, while requesting additional gel analysis only for selected constructs. This helps align cost and timeline with scientific need.
Counterion, salt form, and formulation can affect solubility, mass, concentration reporting, and biological compatibility. CPP-containing molecules may be supplied as TFA salts, acetate salts, chloride salts, ammonium salts, or other forms depending on purification and exchange conditions. Oligonucleotide components may also introduce sodium, ammonium, or other counterions.
If the downstream assay is sensitive to TFA, sodium, phosphate, organic solvent, or other components, the preferred form should be stated. For cell-based studies, researchers may request lyophilized material after desalting or buffer exchange, with reconstitution in nuclease-free water or a defined buffer. For quantitative work, teams should clarify whether they require dry-weight reporting, UV-based concentration, or both.
Quantity reporting for CPP-oligonucleotide conjugates can be more complex than for simple peptides. Lyophilized mass may include salt, water, and counterions, while UV absorbance reflects the oligonucleotide component. A concentration prepared from dry weight alone may differ from a concentration calculated by absorbance. For precise dosing in cell-based assays, this distinction should be understood.
Procurement teams should specify whether they need total amount, nmol amount, concentration after reconstitution, aliquoting, or a certificate indicating calculation method. If the conjugate will be used across multiple experiments, aliquoting may reduce freeze-thaw cycles and improve consistency. If the molecule is prone to adsorption, low-binding containers and appropriate concentration ranges should be considered.
CPP-oligonucleotide conjugates require coordination between conjugation chemistry, purification strategy, analytical method selection, and documentation. Creative Peptides can support CPP-oligonucleotide conjugate projects that require peptide-related technical input, purification planning, identity confirmation, purity assessment, and project-specific documentation. The most productive projects begin with a clear discussion of sequence design, linker chemistry, target scale, downstream application, required purity, and analytical expectations.
For early discovery projects, Creative Peptides can help researchers think through practical questions such as whether the CPP sequence may create solubility concerns, whether a linker may improve accessibility, whether purification should emphasize reversed-phase or ion-exchange behavior, and what level of QC documentation is appropriate for the intended experiment. For more demanding studies, additional attention can be given to orthogonal characterization, formulation preferences, storage recommendations, and batch-to-batch comparability.
The best inquiry includes the peptide sequence, oligonucleotide sequence or modification description, desired attachment site, linker preference if known, target quantity, required purity, intended assay, preferred final form, and documentation requirements. Providing this information early allows the project team to set realistic expectations for feasibility, recovery, analytical confirmation, and delivery of usable material.
If you are planning a CPP-oligonucleotide conjugate project, define the downstream use, required purity, analytical documentation, formulation preference, and storage conditions during inquiry. Clear QC expectations at the beginning of the project help ensure that the final conjugate is not only synthesized, but purified, confirmed, and reported in a way that supports confident downstream research.
They combine the high polarity and negative charge of oligonucleotides with the positive charge, hydrophobicity, and adsorption tendencies of CPPs. This can cause broad peaks, similar impurity profiles, aggregation, and recovery loss during purification.
LC-MS is commonly used when suitable because it can connect chromatographic peaks with molecular weight confirmation. MALDI-TOF may also be useful for larger or difficult conjugates.
HPLC purity is important, but it does not always prove identity. A strong QC package often combines analytical HPLC with mass confirmation and clear concentration or amount reporting.
Cell-based studies usually need higher purity than early screening because free CPP, free oligonucleotide, salts, solvents, or aggregates may affect biological readouts. The exact target should be defined based on assay sensitivity and downstream use.
A useful QC package should include conjugate identity, analytical HPLC purity, molecular weight confirmation where feasible, amount or concentration reporting, final form, and storage and handling recommendations.
